Literature DB >> 23471852

Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study.

George F Mells1, Greta Pells, Julia L Newton, Andrew J Bathgate, Andrew K Burroughs, Michael A Heneghan, James M Neuberger, Darren B Day, Samantha J Ducker, Richard N Sandford, Graeme J Alexander, David E J Jones.   

Abstract

UNLABELLED: Primary biliary cirrhosis (PBC) has a complex clinical phenotype, with debate about the extent and specificity of frequently described systemic symptoms such as fatigue. The aim of this study was to use a national patient cohort of 2,353 patients recruited from all clinical centers in the UK to explore the impact of disease on perceived life quality. Clinical data regarding diagnosis, therapy, and biochemical status were collected and have been reported previously. Detailed symptom phenotyping using recognized and validated symptom assessment tools including the PBC-40 was also undertaken and is reported here. Perception of poor quality of life and impaired health status was common in PBC patients (35% and 46%, respectively) and more common than in an age-matched and sex-matched community control group (6% and 15%, P < 0.0001 for both). Fatigue and symptoms of social dysfunction were associated with impaired perceived quality of life using multivariate analysis. Fatigue was the symptom with the greatest impact. Depression was a significant factor, but appeared to be a manifestation of complex symptom burden rather than a primary event. Fatigue had its greatest impact on perceived quality of life when accompanied by symptoms of social dysfunction, suggesting that maintenance of social networks is critical for minimizing the impact of fatigue.
CONCLUSION: The symptom burden in PBC, which is unrelated to disease severity or ursodeoxycholic acid response, is significant and complex and results in significant quality of life deficit. The complexity of symptom burden, and its lack of relation to disease severity and treatment response, suggest that specific approaches to symptom management are warranted that address both symptom biology and social impact.
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23471852     DOI: 10.1002/hep.26365

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  47 in total

1.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

Review 2.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

Review 3.  Creating an effective clinical registry for rare diseases.

Authors:  Hedwig Ma D'Agnolo; Wietske Kievit; Raul J Andrade; Tom Hemming Karlsen; Heiner Wedemeyer; Joost Ph Drenth
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

4.  Complementary and Alternative Medicine Use in United States Adults With Liver Disease.

Authors:  Jacqueline B Henson; Cristal L Brown; Shein-Chung Chow; Andrew J Muir
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

Review 5.  [Modern treatment of primary biliary cholangitis].

Authors:  C P Strassburg
Journal:  Internist (Berl)       Date:  2018-01       Impact factor: 0.743

6.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

7.  Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Authors:  Jennifer Y Lee; Christopher J Danford; Hirsh D Trivedi; Elliot B Tapper; Vilas R Patwardhan; Alan Bonder
Journal:  Dig Dis Sci       Date:  2019-01-10       Impact factor: 3.199

8.  Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.

Authors:  Minami Yagi; Atsushi Tanaka; Tadashi Namisaki; Atsushi Takahashi; Masanori Abe; Akira Honda; Yasushi Matsuzaki; Hiromasa Ohira; Hitoshi Yoshiji; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-04-16       Impact factor: 7.527

9.  Cholestatic pruritus: Emerging mechanisms and therapeutics.

Authors:  Sagar P Patel; Chirag Vasavda; Byron Ho; James Meixiong; Xinzhong Dong; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

Review 10.  [Primary biliary cholangitis-established and novel therapies].

Authors:  M Vetter; A E Kremer
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.